The present invention pertains to a method for producing induced pluripotent stem cells, and more specifically, to a method for producing induced pluripotent stem cells using RNA nanoparticles for cell transformation, wherein: cell transformation can be effectively performed without genetic modification by producing induced pluripotent stem cells using self-assembled RNA nanoparticles including at least one RNA selected from the group consisting of messenger RNA for expressing transcription factors which induce somatic cells and adult stem cells to be dedifferentiated into induced pluripotent stem cells, micro RNA facilitating the dedifferentiation process, and small interfering RNA; the production efficiency of iPSCs can be maximized by adjusting structural properties and activity; and low gene loading efficiency can be overcome by applying an infinite replication process to incorporate high concentrations of RNA in RNA nanoparticles.

The invention relates to induced pluripotent stem cells that are generated from cells, for example Adult Stem Cells, that are conditionally-immortalisable. In particular, the invention relates to induced pluripotent stem cells generated from stem cell lines comprising a controllable transgene for conditional immortalisation, and the progeny of those induced pluripotent stem cells. Induced pluripotent stem cells, progeny cells derived from those pluripotent cells, compositions comprising those cells, methods of making all of those cells, and uses of all of those cells are also described.

The present invention relates to iPSC produced from fibroblast obtained from a subject affected by a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and uses thereof. The present invention also relates to a cortical neural progenitor cell or a terminally differentiated cortical glutamatergic or gabaergic neuronal cell or a neural crest stem cell line, a mesenchymal stem cell line produced from the iPSC or iPSC line. The invention also relates to method for identifying a compound for the treatment and/or prevention of a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and to a LSD1 inhibitor or a HDAC2 inhibitor for use in the treatment of such disorders.

The present invention relates to artificial transcription factors (ATFs) that alter gene expression, including inducing pluripotency in cells or promoting the conversion of cells to specific cell fates. In particular, provided herein is a zinc-finger based ATF library that can be screened in cells by looking for expression of a specific gene (e.g., reporter expression), monitoring for cell surface markers or morphology, or via functional assays.

A method for producing pluripotent stem cells includes a step of performing suspension culture of pluripotent stem cells under a condition in which an amount, which is calculated by the following Equation (1), of WNT protein contained in a unit of a medium in contact with a unit area of a cell surface of a pluripotent stem cell is maintained at 2.9×10.sup.2 μg/mL.Math.cm.sup.2 or less.

(Amount of WNT protein contained in unit of medium in contact with unit area of cell surface)=(concentration of WNT protein in medium)/(surface area in contact with medium per cell)  (1)

Provided are: a composition for inducing direct conversion from somatic cells into common myeloid progenitor cells, the composition including a chemical cocktail; a method of direct conversion of somatic cells into common myeloid progenitor cells and macrophages by using the composition; common myeloid progenitor cells or macrophages prepared by the method; a pharmaceutical composition for preventing or treating fibrosis or scars, cell therapeutics, a composition for screening drugs, and a 3D printable biomaterial composition for fabricating artificial tissues, each using the common myeloid progenitor cells or the macrophages.

Disclosed is a method for inducing direct reprogramming of urine cells into renal progenitor cells and a pharmaceutical composition including the renal progenitor cells reprogrammed by the method for preventing or treating renal cell injury disease. The method can make the mass production of customized reprogrammed renal progenitor cells by using urine cells, which are somatic cells easily and repeatedly obtainable without inconvenience and pain and as such, can be applied to incurable disease fields expandable to the renal injury therapy and kidney regeneration fields and to the production of cell therapy products.

The invention is in the field of cell culturing. More specifically, it is in the field of generating and expanding myogenic cells from induced pluripotent stem (i PS) cells. The invention relates inter alia to cells generated and expanded via such a method, a growth medium specifically suited for the purpose of expanding isolated myogenic cells, and methods for screening compounds on cell structures such as myotubes and myofibers.

The present invention is a method of creating a population of hemogenic endothelial cells with arterial specification and enhanced T cell potential. In one embodiment, the method uses ETS transgene induction at the mesodermal stage of differentiation. In another embodiment, the method activates ERK and NOTCH signaling at the mesodermal stage of differentiation.

The present invention relates to: a method for producing immunocytes, specifically induced natural killer T (iNKT) cells that are induced by direct reprogramming of isolated somatic cells, and chimeric antigen receptor (CAR)-iNKT cells into which a CAR gene encoding a CAR is introduced; iNKT cells produced by the method; and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, comprising the iNKT cells.

The method according to the present invention can produce, through direct reprogramming, iNKT cells or iNKT cells into which a CAR gene is introduced, from isolated cells so as to simplify the production process and shorten production time, thereby reducing costs, to have excellent NKT cell production efficiency, and to ensure safety according to the production without passing through induced pluripotent stem cells, thereby having an excellent NKT cell production effect distinguished from that of a conventional reprogramming technique. In addition, the iNKT cells or iNKT cells into which a CAR gene is introduced, which are produced by the method, have an excellent cancer cell killing ability, and thus can be effectively used as a cell therapy composition or a pharmaceutical composition for preventing or treating cancer.